Among the medications to treathypertension (high blood pressure), Edarbi (azilsartan) is categorized as anangiotensin II receptor antagonist (ARB)and is used alone or concurrently with other medications to treat high blood pressure.It is used for adults 18 years or older.
High blood pressure is a significant risk factor for cardiovascular disease. In the United States, it affects at least 1 in 3 adults and can lead to the death of 1 in every 7 individuals.
If your healthcare provider has prescribed azilsartan to manage your high blood pressure, note there are a number of potential side effects that may require medical attention, especially if you are on non-steroidal anti-inflammatory drug (NSAID) treatment or you are pregnant.
IPGGutenbergUKLtd / iStock / Getty Images
Mild to Moderate Side Effects
A 2011 study examined the use of azilsartan to treat high blood pressure. Among the side effects noticed in clinical trials with 4,814 patients,diarrheawas the most common occurring in patients who were taking an 80-milligram dose of the medication.
Other symptoms that don’t necessarily require medical attention, unless they continue to be ongoing symptoms, include:
Report any side effects, even mild ones, to your healthcare provider.
Serious Side Effects
Among the reported serious side effects that require immediate medical attention are the following:
Your healthcare provider may note these abnormal findings in blood tests:
For incidents of these adverse side effects, your healthcare provider or you should send a report to the Food and Drug Administration’sFDA MedWatch Adverse Reporting Programonline or call 1-800-332-1088.
Azilasartan and PregnancyIf you are pregnant,azilsartan can harm the fetus. Discontinue taking azilsartan immediately.Medications that affect therenin-angiotensin systemreduce the fetus’s renal function, resulting in oligohydramnios (too little amniotic fluid around the fetus) that can lead to lung underdevelopment (hypoplasia), skeletal deformation including underdevelopment of the skull, and low blood pressure (hypotension) during the second and third trimesters of pregnancy, which may increase the risk of fetal and neonatal death.Frequent ultrasound examinations are recommended throughout the pregnancy to evaluate the intra-amniotic fluid along with testing of the fetus based on the trimester of the pregnancy.
Azilasartan and Pregnancy
If you are pregnant,azilsartan can harm the fetus. Discontinue taking azilsartan immediately.Medications that affect therenin-angiotensin systemreduce the fetus’s renal function, resulting in oligohydramnios (too little amniotic fluid around the fetus) that can lead to lung underdevelopment (hypoplasia), skeletal deformation including underdevelopment of the skull, and low blood pressure (hypotension) during the second and third trimesters of pregnancy, which may increase the risk of fetal and neonatal death.Frequent ultrasound examinations are recommended throughout the pregnancy to evaluate the intra-amniotic fluid along with testing of the fetus based on the trimester of the pregnancy.
If you are pregnant,azilsartan can harm the fetus. Discontinue taking azilsartan immediately.
Medications that affect therenin-angiotensin systemreduce the fetus’s renal function, resulting in oligohydramnios (too little amniotic fluid around the fetus) that can lead to lung underdevelopment (hypoplasia), skeletal deformation including underdevelopment of the skull, and low blood pressure (hypotension) during the second and third trimesters of pregnancy, which may increase the risk of fetal and neonatal death.
Frequent ultrasound examinations are recommended throughout the pregnancy to evaluate the intra-amniotic fluid along with testing of the fetus based on the trimester of the pregnancy.
When to Talk to Your Healthcare Provider
There are certain conditions and medications that may increase the risk of side effects if azilsartan has been prescribed. For example, azilsartan can not be administered to patients with diabetes who are being treated with aliskiren-containing products.
Elderly patients who are currently treated with diuretic therapy and are volume-depleted (a deficit of extracellular fluid volume), have compromised kidney function, and are taking NSAIDs, (including COX-2 inhibitors) with azilsartan may experience side effects resulting in worsening kidney function that can lead to acute kidney failure.
These side effects typically can be reversed. However, patients will need to be monitored more frequently to check their kidney function.
Other concerns include:
Be sure to always consult with your healthcare provider which prescription and over-the-counter drugs you are taking for specific conditions to minimize the risk of side effects.
Many people with high blood pressure will need to take more than one medication to control it to reach a healthy goal and reduce their risk of cardiovascular disease. Azilsartan is an ARB, but other types of drugs are used for the treatment of high blood pressure. Other medications include:
Treating hypertension is a component of managing potential cardiovascular risk. Other measures, when deemed relevant, include lipid control, diabetes management, antithrombotic therapy (treating blood clots), cigarette smoking termination, exercise, and reducing sodium consumption.
6 SourcesVerywell Health uses only high-quality sources, including peer-reviewed studies, to support the facts within our articles. Read oureditorial processto learn more about how we fact-check and keep our content accurate, reliable, and trustworthy.MedlinePlus.Azilsartan.Jones JD, Jackson SH, Agboton C, Martin TS.Azilsartan medoxomil (Edarbi): The eighth angiotensin II receptor blocker.P T.2011;36(10):634-640.Centers for Disease Control and Prevention.Estimated hypertension prevalence, treatment, and control among U.S. adults.National Institutes of Health DailyMed.Label: EDARBI-azilsartan.Edarbi.Edarbi (azilsartan medoxomil) safety & tolerability.Food and Drug Administration.Edarbi (azilsartan medoxomil) tablets.
6 Sources
Verywell Health uses only high-quality sources, including peer-reviewed studies, to support the facts within our articles. Read oureditorial processto learn more about how we fact-check and keep our content accurate, reliable, and trustworthy.MedlinePlus.Azilsartan.Jones JD, Jackson SH, Agboton C, Martin TS.Azilsartan medoxomil (Edarbi): The eighth angiotensin II receptor blocker.P T.2011;36(10):634-640.Centers for Disease Control and Prevention.Estimated hypertension prevalence, treatment, and control among U.S. adults.National Institutes of Health DailyMed.Label: EDARBI-azilsartan.Edarbi.Edarbi (azilsartan medoxomil) safety & tolerability.Food and Drug Administration.Edarbi (azilsartan medoxomil) tablets.
Verywell Health uses only high-quality sources, including peer-reviewed studies, to support the facts within our articles. Read oureditorial processto learn more about how we fact-check and keep our content accurate, reliable, and trustworthy.
MedlinePlus.Azilsartan.Jones JD, Jackson SH, Agboton C, Martin TS.Azilsartan medoxomil (Edarbi): The eighth angiotensin II receptor blocker.P T.2011;36(10):634-640.Centers for Disease Control and Prevention.Estimated hypertension prevalence, treatment, and control among U.S. adults.National Institutes of Health DailyMed.Label: EDARBI-azilsartan.Edarbi.Edarbi (azilsartan medoxomil) safety & tolerability.Food and Drug Administration.Edarbi (azilsartan medoxomil) tablets.
MedlinePlus.Azilsartan.
Jones JD, Jackson SH, Agboton C, Martin TS.Azilsartan medoxomil (Edarbi): The eighth angiotensin II receptor blocker.P T.2011;36(10):634-640.
Centers for Disease Control and Prevention.Estimated hypertension prevalence, treatment, and control among U.S. adults.
National Institutes of Health DailyMed.Label: EDARBI-azilsartan.
Edarbi.Edarbi (azilsartan medoxomil) safety & tolerability.
Food and Drug Administration.Edarbi (azilsartan medoxomil) tablets.
Meet Our Medical Expert Board
Share Feedback
Was this page helpful?Thanks for your feedback!What is your feedback?OtherHelpfulReport an ErrorSubmit
Was this page helpful?
Thanks for your feedback!
What is your feedback?OtherHelpfulReport an ErrorSubmit
What is your feedback?
